eyecare pharmaceutical company harrow health inc said it has agreed to buy the exclusive us commercial rights to five ophthalmic drugs from novartis ag for up to 175 million harrow will pay 130 million at closing of the deal with an additional 45 million payable upon the commercial availability of one of the drugs triesence which is expected in the second half of 2023 as part of the deal harrow will get the us rights to five drugs in total including ilevero nevanac vicamox and maxidex in addition to triesence all the drugs have been approved by the us food and drug administration harrow said assuming the deal closes in the first quarter of 2023 harrow expects 2023 revenue of 135 million to 143 million the company said harrow chairman and chief executive mark baum described the deal as a landmark for the company also on wednesday harrow said it has priced an underwritten registered offering of nearly 24 million shares of common stock at a price of 1052 a share for aggregate gross proceeds of 25 million the company also said it has commenced an underwritten registered public offering of 100 million aggregate principal amount of senior notes due 2027 the company said it plans to use the proceeds from both offerings for acquisition expenses write to will feuer at willfeuerwsjcom